Author(s): Rizos CV, Elisaf MS, Rizos CV, Elisaf MS
Abstract Share this page
Abstract Type 2 diabetes mellitus is a rising cause of cardiovascular morbidity and mortality. A number of studies have also identified diabetic patients as having increased risk for the development of cancer. Metformin is a widely prescribed antidiabetic drug with an established efficacy coupled with a favorable safety profile and low cost. An increasing number of studies have associated metformin treatment with a decrease of cancer risk. Moreover, metformin has also been associated with improved outcomes in cancer patients. These possible pleiotropic effects of metformin may establish metformin as a cancer prevention and treatment option. However, any favorable effects of metformin on cancer are not always corroborated by clinical trials. Larger studies are expected to better investigate the possible antineoplastic effects of metformin. Copyright © 2013 Elsevier B.V. All rights reserved.
This article was published in Eur J Pharmacol
and referenced in Journal of Thyroid Disorders & Therapy